EGFR and neoplasm: Furthermore, the combination of EGFR-TKI and a β-catenin inhibitor suppressed the development of these adaptive persisters and improved overall survival of mouse tumor xenograft models, suggesting that combined EGFR and β-catenin inhibition might be a promising strategy for EGFR-mutant lung cancer.